d into the human body."
Insulin, one of the compounds previously analyzed, is a reliable proof of principle for the technology. Because it is such a large molecule, and a protein, it has been traditionally very difficult to deliver through the skin unless it was given via an injection. During this study, it passed through even at low concentrations in the Company's proprietary formulation.
In addition, two other large-market drugs Estradiol, used to treat the symptoms of menopause and Paclitaxel, a prescription cancer drug, were tested. It is Fuse's hypothesis, based on the success of their research, that they will be successful in the delivery of therapeutic doses of each, within their matrix, in a simple roll-on application.
The primary benefits that may develop from these studies are:
Enhanced delivery option for complex API's
Improved bio-availability or enhanced absorption in the body
Stronger product efficacy
Enhanced ease of use (A simple roll-on application)
Expansion of therapeutic options for acute, rapid onset conditions
Data from these preliminary research studies show that with little requirement for optimization, the technology can provide for the transdermal delivery of drugs at clinically relevant doses for the treatment of a wide variety of ailments and diseases. Most compounds showed improvement of delivery over each time-point during the course of the study. The lack of plateaus would suggest that delivery improves with time and can be sustained for periods much greater than twenty-four hours.
This latest research is particularly relevant to the active licensing and M&A efforts of the company.
The full Round II Research report can be found by visiting the "Clinical Research" section of the Fuse Science Investor Relations page here: Page: 1 2 3 Related medicine technology :1
. BioMed Realty And Wexford Science & Technology Complete Merger2
. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition3
. Lilly Statement on Indiana Biosciences Research Institute4
. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference5
. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline6
. Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference7
. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference8
. Record Use of At-the-Market (ATM) Offerings Continues in 2013 with $161 Million Raised by U.S. Life Sciences Companies in First Quarter, Reports Brinson Patrick9
. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland10
. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference11
. Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support